Contrasting Karyopharm Therapeutics (NASDAQ:KPTI) and Alpha Cognition (NASDAQ:ACOG)

Alpha Cognition (NASDAQ:ACOG) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Profitability

This table compares Alpha Cognition and Karyopharm Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-153.61%	-54.60%	-43.47%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

Analyst Ratings

This is a summary of current recommendations and price targets for Alpha Cognition and Karyopharm Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	5	0	3.00
Karyopharm Therapeutics	1	2	3	1	2.57

Alpha Cognition presently has a consensus target price of $18.00, suggesting a potential upside of 95.44%. Karyopharm Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 549.72%. Given Karyopharm Therapeutics’ higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Alpha Cognition.

Earnings and Valuation

This table compares Alpha Cognition and Karyopharm Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$15.26 million	13.14	-$20.67 million	($1.10)	-8.37
Karyopharm Therapeutics	$146.07 million	0.27	-$196.04 million	($13.09)	-0.14

Alpha Cognition has higher earnings, but lower revenue than Karyopharm Therapeutics. Alpha Cognition is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility and Risk

Alpha Cognition has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.

Summary

Alpha Cognition beats Karyopharm Therapeutics on 8 of the 15 factors compared between the two stocks.

About Alpha Cognition

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.